MindWalk Holdings Corp. (HYFT)

NASDAQ: HYFT · Real-Time Price · USD
1.630
-0.100 (-5.78%)
Oct 28, 2025, 4:00 PM EDT - Market closed
-5.78%
Market Cap75.23M
Revenue (ttm)18.21M
Net Income (ttm)-21.09M
Shares Out 46.15M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume252,348
Open1.680
Previous Close1.730
Day's Range1.630 - 1.775
52-Week Range0.270 - 3.246
Beta0.70
Analystsn/a
Price Targetn/a
Earnings DateDec 9, 2025

About HYFT

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 202... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 3, 2017
Employees 102
Stock Exchange NASDAQ
Ticker Symbol HYFT
Full Company Profile

Financial Performance

In 2025, MindWalk Holdings's revenue was 24.52 million, an increase of 0.01% compared to the previous year's 24.52 million. Losses were -30.23 million, 15.8% more than in 2024.

Financial numbers in CAD Financial Statements

News

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R...

7 days ago - Business Wire

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

MindWalk Holdings (HYFT) has pivoted to an asset-light, AI-driven techbio platform, leveraging its HYFT and LensAI technologies for in silico drug discovery. LensAI's early successes include a dual-ac...

11 days ago - Seeking Alpha

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran...

13 days ago - Business Wire

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

MindWalk Holdings Corp. (NASDAQ:HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call October 9, 2025 1:00 PM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Direct...

19 days ago - Seeking Alpha

MindWalk Announces Share Repurchase Program

AUSTIN, Texas--(BUSINESS WIRE)---- $hyft #AI--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in Mind...

19 days ago - Business Wire

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-desi...

5 weeks ago - Business Wire

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

MindWalk Holdings Corp. (NASDAQ:HYFT) Q1 2026 Earnings Call September 15, 2025 10:30 AM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Director Joseph Scheffler - Interim C...

6 weeks ago - Seeking Alpha

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-...

6 weeks ago - Business Wire

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announ...

7 weeks ago - Business Wire

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global In...

2 months ago - Business Wire

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...

2 months ago - Business Wire

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

WASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)--Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced...

2 months ago - Business Wire

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...

2 months ago - Business Wire

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q4 2025 Earnings Call July 29, 2025 10:30 AM ET Company Participants Jennifer Lynne Bath - CEO, President & Non-Independent Director Joseph Scheffler - Inte...

3 months ago - Seeking Alpha

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA”, “Company”, “we” or “us”) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-gen...

3 months ago - Business Wire

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, t...

3 months ago - Business Wire

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation ...

3 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation ...

3 months ago - Business Wire

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a company operating at the convergence of TechBio and biological intelligence, today ...

3 months ago - Business Wire

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber ...

4 months ago - Business Wire

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study support...

4 months ago - Business Wire

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise A...

4 months ago - Business Wire

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonst...

4 months ago - Business Wire

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AUSTIN, Texas--(BUSINESS WIRE)---- $AMD #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four d...

Other symbols: AMD
5 months ago - Business Wire

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and p...

5 months ago - Business Wire